(Precision Vaccinations)

UK-based Synairgen plc announced on January 13, 2021, that the first patient had been dosed in the United Kingdom as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001) for the treatment of hospitalized COVID-19 patients.

Interferon beta (‘IFN-beta’) is a naturally-occurring protein, which orchestrates the body’s antiviral responses. It is used widely in treating multiple sclerosis and is a safe and well-tolerated drug.


Read more…